Oxidative stress and autophagy-mediated immune patterns and tumor microenvironment infiltration characterization in gastric cancer

被引:0
作者
Liu, Jifeng [1 ]
Zhang, Biao [1 ]
Zhang, Yunshu [1 ]
Zhao, Huahui [1 ]
Chen, Xu [1 ]
Zhong, Lei [1 ]
Shang, Dong [1 ]
机构
[1] Dalian Med Univ, Affiliated Hosp 1, Dept Gen Surg, Dalian, Peoples R China
来源
AGING-US | 2023年 / 15卷 / 21期
关键词
oxidative stress; autophagy; gastric cancer; molecular features; tumor microenvironment; INFLAMMATION; SURVIVAL;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Recent years have seen a sharp rise in the amount of research on the connection between oxidative stress, autophagy, and cancer cells. However, the significant functions of oxidative stress and autophagy-related genes (OARGs) in gastric cancer (GC) are yet to be investigated integrally. Therefore, it will be a new and promising concept to search for novel OARG-related biomarkers to predict the prognosis and treatment response of GC. First, we assessed changes in prognosis and tumor microenvironment (TME) characteristics across the various oxidative stress and autophagy-related modification patterns based on a detailed analysis of 17 OARGs with prognostic significance of 808 GC samples. We identified three distinct OARG alteration patterns which displayed unique biological characteristics and immune cell infiltration features. Using principal component analysis methods, the OARGscore was developed to evaluate the OARG modification patterns of certain tumors. The negative connection between OARGscore and immune cells was statistically significant. Increased survival, a higher incidence of mutations, and a better response to immunotherapy were all predicted to be related to patients' high-OARGscore. In addition, the candidate chemotherapeutic drugs were predicted using the oncoPredict program. The low-OARGscore group was predicted to benefit more from Ribociclib, Alisertib, Niraparib, Epirubicin, Olaparib, and Axitinib, while patients in the high-OARGscore group were predicted to benefit more from Afatinib, Oxaliplatin, Paclitaxel, 5-Fluorouracil, Dabrafenib and Lapatinib. Our findings offer a specific method for predicting a patient's prognosis and susceptibility to immunotherapy, as well as a promising insight of oxidative stress and autophagy in GC.
引用
收藏
页码:12513 / 12536
页数:24
相关论文
共 56 条
[51]   Robotic- versus laparoscopic-assisted distal gastrectomy with D2 lymphadenectomy for advanced gastric cancer based on propensity score matching: short-term outcomes at a high-capacity center [J].
Ye, Shan-ping ;
Shi, Jun ;
Liu, Dong-ning ;
Jiang, Qun-guang ;
Lei, Xiong ;
Tang, Bo ;
He, Peng-hui ;
Zhu, Wei-quan ;
Tang, He-chun ;
Li, Tai-yuan .
SCIENTIFIC REPORTS, 2020, 10 (01)
[52]   A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer [J].
Ye, Ying ;
Dai, Qinjin ;
Qi, Hongbo .
CELL DEATH DISCOVERY, 2021, 7 (01)
[53]   Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model [J].
Yoon, Seon-Jin ;
Park, Jungmin ;
Shin, Youngmin ;
Choi, Yuna ;
Park, Sahng Wook ;
Kang, Seok-Gu ;
Son, Hye Young ;
Huh, Yong-Min .
BMC CANCER, 2020, 20 (01)
[54]   Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma [J].
Zhang, Xin ;
Zhuge, Jinke ;
Liu, Jinhui ;
Xia, Zhijia ;
Wang, Huixiong ;
Gao, Qiang ;
Jiang, Hao ;
Qu, Yanyu ;
Fan, Linlin ;
Ma, Jiali ;
Tan, Chunhua ;
Luo, Wei ;
Luo, Yong .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[55]   Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer [J].
Zhao, Songyun ;
Zhang, Xin ;
Gao, Feng ;
Chi, Hao ;
Zhang, Jinhao ;
Xia, Zhijia ;
Cheng, Chao ;
Liu, Jinhui .
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[56]   Integrative Analysis of Multi-Omics Identified the Prognostic Biomarkers in Acute Myelogenous Leukemia [J].
Zheng, Jiafeng ;
Zhang, Tongqiang ;
Guo, Wei ;
Zhou, Caili ;
Cui, Xiaojian ;
Gao, Long ;
Cai, Chunquan ;
Xu, Yongsheng .
FRONTIERS IN ONCOLOGY, 2020, 10